Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Awake-102
- Development stage
- Preclinical
- Lead developer
- Matter Bio
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Awake-102 is a preclinical-stage microbial immunotherapy being developed by Matter Bio for the treatment of refractory ovarian cancer. The drug utilizes the LM-LLO-TT platform, which consists of a live-attenuated *Listeria monocytogenes* (LM) vector engineered to express and secrete a fusion protein of listeriolysin O (LLO) and a tetanus toxoid (TT) recall antigen. Upon administration, the *Listeria* vector selectively localizes within the immunosuppressive tumor microenvironment. The delivery of the tetanus antigen is designed to recruit and reactivate pre-existing memory T cells—originally generated through routine childhood tetanus vaccinations—to attack the tumor cells. This approach aims to convert immunologically "cold" tumors into "hot" tumors by bypassing the need for the de novo priming of T cells against neoantigens.
- Other names
- LM-LLO-TT
02
Targets
LLO (Listeriolysin O)Tetanus toxoid-specific memory T cell
Beyond the preview
Go deeper on Awake-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Awake-102.